Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Another market introduction for Lilly's SERM

Jan. 27, 1999

Livial not available in Germany for osteoporosis prevention

Jan. 27, 1999

Potent ACAT inhibitors for lipid disorders from Sankyo

Jan. 27, 1999

Amylin reports additional data from long-term pramlintide studies

Jan. 27, 1999

Japanese authorities approve Viagra

Jan. 26, 1999

New findings on the role of IFN-alpha in diabetes reported

Jan. 26, 1999

WHO maintains importance of male contraceptive research

Jan. 26, 1999

Hypoglycemic/hypoinsulinemic chromium complexes designed at Otsuka

Jan. 26, 1999

New insulin sensitizer is a coligand for PPARalpha and PPARgamma receptors

Jan. 25, 1999

FDA grants priority review to SB's Avandia

Jan. 22, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...